HUYA Appoints Vice President Of Commercial Planning
This article was originally published in Scrip
HUYA Bioscience International has appointed Scott Garrett vice president, commercial planning. Scott brings over 20 years of commercial experience in drugs and devices for oncology and cardiovascular disease and he previously held positions in companies such as Celladon, Mallinckrodt, Gilead, Johnson and Johnson, Boston Scientific and Nycomed Amersham (now GE Healthcare). His previous responsibilities include sales and marketing, commercial planning, product launch, healthcare economics, reimbursement, advocacy development, life cycle management and business development for brands such as Ceretec, Taxus, Natrecor, Ranexa and Ofirmev.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.